Zoetis (ZTS) Scheduled to Post Earnings on Monday

Zoetis (NYSE:ZTS) is set to announce its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $1.46 per share for the quarter. Zoetis has set its FY24 guidance at $5.78-5.88 EPS and its FY 2024 guidance at 5.780-5.880 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.41 earnings per share. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Zoetis Price Performance

Zoetis stock opened at $181.95 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a fifty day simple moving average of $188.97 and a 200-day simple moving average of $178.69. The stock has a market cap of $82.43 billion, a P/E ratio of 35.61, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.66%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ZTS. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.